Table 1 Baseline characteristics of European Prospective Investigation into Cancer -Norfolk cohort participants by categories of C-reactive protein and in total recruited in 1993–1997*
All participants | C-reactive protein (mg/L) | |||||
|---|---|---|---|---|---|---|
≤1 | 1.1-3 | 3.1-10 | >10 | |||
n = 14,228 | n = 5,460 | n = 5,249 | n = 2,927 | n = 592 | ||
Age | 58.0 (9.0) | 55.7 (8.8) | 59.0 (8.8) | 60.1 (8.8) | 60.7 (8.6) | |
Haemoglobin A1c (%)** | 5.3 (0.7) | 5.1 (0.6) | 5.3 (0.6) | 5.4 (0.7) | 5.6 (0.9) | |
Body mass index (Kg/m2) | 26.1 (3.7) | 24.7 (3.0) | 26.5 (3.4) | 27.8 (4.2) | 27.5 (4.8) | |
Waist Circumference (cm) | 87.3 (12.1) | 83.6 (11.2) | 88.5 (11.6) | 91.5 (12.2) | 91.5 (13.0) | |
Alcohol (units/week) | 7.1 (9.1) | 7.2 (8.7) | 7.2 (9.5) | 6.7 (9.5) | 6.5 (8.6) | |
Sex (% male) | 6,211 (43.7 %) | 2,412 (44.2 %) | 2,361 (45.0 %) | 1,177 (40.2 %) | 261 (44.1 %) | |
Smoking | Current | 1,488 (10.5 %) | 445 (8.2 %) | 530 (10.2 %) | 413 (14.3 %) | 100 (17.0 %) |
Former | 5,825 (41.3 %) | 2,060 (37.9 %) | 2,262 (43.4 %) | 1,249 (43.1 %) | 254 (43.3 %) | |
Never | 6,809 (48.2 %) | 2,926 (53.9 %) | 2,415 (46.4 %) | 1,235 (42.6 %) | 233 (39.7 %) | |
Physical activity | Inactive | 3,958 (27.8 %) | 1,196 (21.9 %) | 1,523 (29.0 %) | 1,016 (34.7 %) | 223 (37.7 %) |
Moderately inactive | 4,104 (28.8 %) | 1,582 (29.0 %) | 1,525 (29.1 %) | 825 (28.2 %) | 172 (29.1 %) | |
Moderately active | 3,370 (23.7 %) | 1,433 (26.3 %) | 1,214 (23.1 %) | 608 (20.8 %) | 115 (19.4 %) | |
Active | 2,796 (19.7 %) | 1,249 (22.9 %) | 987 (18.8 %) | 478 (16.3 %) | 82 (13.9 %) | |
Prevalent disease | Cancer | 733 (5.2 %) | 239 (4.4 %) | 287 (5.5 %) | 171 (5.8 %) | 36 (6.1 %) |
Myocardial Infarction | 392 (2.8 %) | 87 (1.6 %) | 162 (3.1 %) | 107 (3.7 %) | 36 (6.1 %) | |
Stroke | 166 (1.2 %) | 41 (0.8 %) | 65 (1.2 %) | 48 (1.6 %) | 12 (2.0 %) | |
Corticosteroid medication use | 408 (2.9 %) | 103 (1.9 %) | 147 (2.8 %) | 121 (4.1 %) | 37 (6.3 %) | |
Postmenopause | 6,129 (76.5 %) | 2,024 (66.4 %) | 2,324 (80.5 %) | 1,505 (86.1 %) | 276 (83.4 %) | |
Hormone replacement therapy (% current use) | 1,751 (21.9 %) | 435 (14.3 %) | 658 (22.8 %) | 542 (31.0 %) | 116 (35.1 %) | |